Recent Updates
Recently added Catalysts
RLAY Positive Sentiment

Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026

Thursday, February 19, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Relay Therapeutics, a clinical-stage company focused on precision medicine, will announce its fourth quarter and full year financial results for 2025 on February 26, 2026. This announcement will follow the close of U.S. financial markets, providing insights into the company's performance and corporate highlights for the fiscal year. As a company developing treatments for cancer and genetic diseases, this update is significant for stakeholders and investors alike.
Price reaction · baseline $9.1 (2026-02-18 close) · hit after-hours · 1 other RLAY headline(s) in the window, move may be shared
day 0 close · peak
-2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Relay Therapeutics is progressing in its development of potentially life-changing therapies.
  • The company is preparing to announce financial results, indicating ongoing operational activities.
  • Highlighting corporate developments reflects potential growth and transparency.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+284%
120-day peak, hindsight
Typical move
11.8%
average across 6 past catalysts
Cash runway
~50 mo
Minimal dilution risk
Lead asset
RLY-8161
Phase 1 · Advanced NRAS-Mutant Melanoma

Full Press Release Details

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report fourth quarter and full year 2025 financial results and corporate highlights after the U.S. financial markets close on Thursday, February 26, 2026.
About Relay Therapeutics

Frequently Asked Questions

When will Relay Therapeutics report its financial results?

Relay Therapeutics will report its financial results on February 26, 2026.

What type of company is Relay Therapeutics?

Relay Therapeutics is a precision medicine company focused on cancer and genetic diseases.

When does the financial report come out?

The financial report will be released after U.S. market close on February 26, 2026.

What is the focus of Relay Therapeutics' therapies?

Relay Therapeutics develops therapies for cancer and genetic disease patients.

ShareAdd on Google
Tags: RLAY Viatris Investor Conferences Healthcare Relay Therapeutics financial results precision medicine cancer treatment genetic disease
Last updated: Feb 19, 2026

Biotech snapshot

Cash runway
$911M liquidity · $18M/mo burn
~50 mo
Minimal dilution risk
Lead asset
RLY-8161Phase 1
Advanced NRAS-Mutant Melanoma →

Catalyst track record

+284%
best trade around RLAY's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for RLAY.

See every catalyst's timing & PoA →